07:50 AM EDT, 07/01/2025 (MT Newswires) -- Apellis Pharmaceuticals ( APLS ) said Tuesday that it will receive up to $300 million from biopharmaceutical company Sobi in exchange for 90% of Apellis' future non-US royalties for Aspaveli to treat patients with rare diseases.

Under a collaboration agreement the companies signed in 2020, Apellis is eligible for tiered royalties on non-US sales of Aspaveli, which range from high teens to high twenties.

The agreement also stipulates that Apellis retains exclusive commercialization rights for systemic pegcetacoplan in the US, where it is known under the brand name Empaveli.